BR112022024539A2 - Vírus sincicial respiratório vivo atenuado - Google Patents

Vírus sincicial respiratório vivo atenuado

Info

Publication number
BR112022024539A2
BR112022024539A2 BR112022024539A BR112022024539A BR112022024539A2 BR 112022024539 A2 BR112022024539 A2 BR 112022024539A2 BR 112022024539 A BR112022024539 A BR 112022024539A BR 112022024539 A BR112022024539 A BR 112022024539A BR 112022024539 A2 BR112022024539 A2 BR 112022024539A2
Authority
BR
Brazil
Prior art keywords
live
respiratory syncytial
atenuated
syncytial virus
viruses
Prior art date
Application number
BR112022024539A
Other languages
English (en)
Inventor
Collins Peter
Buchholz Ursula
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of BR112022024539A2 publication Critical patent/BR112022024539A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571Demonstrated in vivo effect
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

VÍRUS SINCICIAL RESPIRATÓRIO VIVO ATENUADO. A presente invenção refere-se a novos vírus sinciciais respiratórios (RSV) recombinantes que têm um fenótipo atenuado. As cepas recombinantes do RSV aqui descritas são adequadas para uso como vacinas de RSV vivo atenuado. Além disso, são providas sequências de polinucleotídeos capazes de codificar os vírus descritos, bem como métodos para produção e uso dos vírus.
BR112022024539A 2020-06-05 2021-06-04 Vírus sincicial respiratório vivo atenuado BR112022024539A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035617P 2020-06-05 2020-06-05
PCT/US2021/036030 WO2021248086A2 (en) 2020-06-05 2021-06-04 Live attenuated respiratory syncytial virus

Publications (1)

Publication Number Publication Date
BR112022024539A2 true BR112022024539A2 (pt) 2022-12-27

Family

ID=76708442

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024539A BR112022024539A2 (pt) 2020-06-05 2021-06-04 Vírus sincicial respiratório vivo atenuado

Country Status (10)

Country Link
US (1) US20230279362A1 (pt)
EP (1) EP4161567A2 (pt)
JP (1) JP2023529836A (pt)
KR (1) KR20230021115A (pt)
CN (1) CN116568323A (pt)
AU (1) AU2021285997A1 (pt)
BR (1) BR112022024539A2 (pt)
CA (1) CA3185143A1 (pt)
MX (1) MX2022015398A (pt)
WO (1) WO2021248086A2 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
EP4190895A1 (en) * 2013-02-08 2023-06-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
US10654898B2 (en) * 2015-01-20 2020-05-19 The United States of America, as represented by the Secretary, Department of Health and Human Serices Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof
US10655109B2 (en) * 2015-12-11 2020-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant respiratory syncytial virus stains with mutations in the M2-2 ORF providing a range of attenuation phenotypes

Also Published As

Publication number Publication date
CN116568323A (zh) 2023-08-08
JP2023529836A (ja) 2023-07-12
US20230279362A1 (en) 2023-09-07
AU2021285997A1 (en) 2023-01-19
WO2021248086A2 (en) 2021-12-09
EP4161567A2 (en) 2023-04-12
WO2021248086A3 (en) 2022-01-13
CA3185143A1 (en) 2021-12-09
KR20230021115A (ko) 2023-02-13
MX2022015398A (es) 2023-04-05

Similar Documents

Publication Publication Date Title
MX2022009429A (es) Composiciones para la inmunizacion contra virus respiratorios.
CO2018005265A2 (es) Vacunas de ácido nucleico para el virus varicela-zóster
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
EA201890999A1 (ru) Вакцина против вируса простого герпеса
CO7160021A2 (es) Virus del herpes aviar recombinantes multivalentes y vacunas para inmunizar especies aviares
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
IN2014MN01714A (pt)
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
EA201991041A1 (ru) Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
MX2022010372A (es) Vacuna contra la infeccion por el virus de la peste porcina africana.
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
CO2022017989A2 (es) Vacunas para la papilomatosis respiratoria recurrente y métodos para usar estas
CL2013002631A1 (es) Virus de la necrosis pancreatica infecciosa (ipnv) avirulento porque comprende proteina vp2 madura.
BR112022024539A2 (pt) Vírus sincicial respiratório vivo atenuado
ZA202305129B (en) Recombinant hvt and uses thereof
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
BR112018011674A2 (pt) cepas do vírus sincicial respiratório recombinante com mutações na orf de m2-2 fornecendo uma faixa de fenótipos de atenuação